Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma.

Hibma JE, Irby D, Liu A, Elmeliegy M, King LE, Gifondorwa D, Jiang S, Poels KE, Soltantabar P, Lon HK, Shtylla B, Wang D, Williams JH, Nicholas T

Open source

DOI: 10.1007/s40262-026-01663-z
Published: 2026 Aug
Container: Clinical pharmacokinetics
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40262-026-01663-z,
  title = {Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma.},
  author = {Hibma JE and Irby D and Liu A and Elmeliegy M and King LE and Gifondorwa D and Jiang S and Poels KE and Soltantabar P and Lon HK and Shtylla B and Wang D and Williams JH and Nicholas T},
  year = {2026},
  journal = {Clinical pharmacokinetics},
  doi = {10.1007/s40262-026-01663-z},
  url = {https://doi.org/10.1007/s40262-026-01663-z}
}

RIS

TY  - JOUR
TI  - Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma.
AU  - Hibma JE
AU  - Irby D
AU  - Liu A
AU  - Elmeliegy M
AU  - King LE
AU  - Gifondorwa D
AU  - Jiang S
AU  - Poels KE
AU  - Soltantabar P
AU  - Lon HK
AU  - Shtylla B
AU  - Wang D
AU  - Williams JH
AU  - Nicholas T
PY  - 2026
JO  - Clinical pharmacokinetics
DO  - 10.1007/s40262-026-01663-z
UR  - https://doi.org/10.1007/s40262-026-01663-z
ER  -

APA

JE, H., D, I., A, L., M, E., LE, K., D, G., S, J., KE, P., P, S., HK, L., B, S., D, W., JH, W., & T, N. (2026). Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma.. Clinical pharmacokinetics. https://doi.org/10.1007/s40262-026-01663-z

Source records

pubmed · retrieved 2026-09-25T12:12:17.254Z